First human trial tests experimental herpes vaccine

This early-stage study tested whether a new experimental vaccine for herpes simplex virus type 2 (HSV-2), which causes genital herpes, is safe for people. The trial involved 69 healthy adults, some with and some without prior herpes infections, who received three injections of either the vaccine or a placebo over six months. Researchers monitored participants for a year to check for side effects and to see if the vaccine triggered an immune response.